Dr. Wolf on the Treatment of High-Risk Patients With Multiple Myeloma
April 20th 2018Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the treatment approach for patients with high-risk multiple myeloma.
Dr. Gordan on Molecular Diagnostics in Biliary Tract Cancers
March 22nd 2018John Gordan, MD, PhD, assistant professor, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how the adoption of molecular diagnostics has helped further treatment efforts in biliary tract cancers.
Dr. Tempero on Emerging Agents in Pancreatic Cancer
March 20th 2018Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the interest in the pegylated hyaluronidase agent, PEGPH20, and clinical trials exploring other emerging agents in pancreatic cancer.
Dr. Kelley on Newly Approved Agents in HCC
March 15th 2018R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the clinical impact of REFLECT and CELESTIAL in hepatocellular carcinoma (HCC).
Dr. Collisson Discusses Developments in Gastric Cancers
March 15th 2018Eric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the focus of clinical trial research and genetic testing in gastrointestinal (GI) cancers.
Dr. Atreya on How the NCCN Guidelines Have Impacted Treatment Options in mCRC
March 14th 2018Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the molecular subgroups in metastatic colorectal cancer (mCRC) and viable treatment options for patients with microsatellite instability (MSI)-high and BRAF-mutated cancers.
Dr. Wolf Discusses Treatment Options for Multiple Myeloma
March 9th 2018Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with multiple myeloma.
Dr. Venook Discusses Adjuvant Chemotherapy Duration in CRC
March 7th 2018Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses adjuvant chemotherapy duration in colon cancer.
Dr. Smith on Acquired Resistance to Targeted Agents for AML
February 7th 2018Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient acquired resistance in quizartinib (AC220) and gilteritinib (ASP2215) in acute myeloid leukemia (AML).
Dr. Wong on Anti-Amyloid Fibril Treatments in AL Amyloidosis
February 6th 2018Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).
Dr. Mannis on Targeted Agents in the Treatment of Patients With AML
February 6th 2018Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval and potential approval of 2 new agents that will provide a more nuanced treatment approach for patients with acute myeloid leukemia (AML).
Dr. Ai on Potential With Mogamulizumab in CTCL
January 23rd 2018Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, speaks to the relevance of mogamulizumab (Poteligeo) in treating Sezary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma
Dr. Smith on the Development of Active Therapeutic Combinations in Acute Myeloid Leukemia
January 23rd 2018Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, discusses developing active therapeutic combinations for the treatment of patients with acute myeloid leukemia